Follistatin 344
Myostatin-pathway modulator (investigational) · Pre-filled pen
Follistatin 344 is studied as a binding protein that neutralises myostatin and related TGF-β-family signals, a pathway that normally acts as a physiological brake on skeletal-muscle growth. By reducing ActRIIB/SMAD-mediated inhibition, it is investigated for a possible shift toward myogenesis and muscle-tissue remodelling. Current understanding rests mainly on laboratory and animal models rather than controlled human trials.
Studied use areas
- Research into lean-muscle development and myogenesis signalling
- Models of myostatin-related muscle wasting and atrophy
- Anti-catabolic / muscle-preservation research
- Body-composition research alongside growth-factor pathways
Safety & status
- Educational information only — not medical advice; use requires physician supervision
- Investigational compound with no approved indication for muscle growth; evidence is largely preclinical
- Myostatin inhibition has broad effects across tissues, so individual risks must be assessed clinically
- Suitability, screening and monitoring are determined by the treating physician
⚕ Clinical note: This card is educational and is not medical advice, a protocol or a promise of results. Follistatin 344 is investigational; any use must be individualised and supervised by a qualified physician.
Evidence: Investigational (Grade D) — mainly preclinical, minimal human data · References: peer-reviewed myostatin and skeletal-muscle physiology literature; preclinical regenerative-medicine and gene-therapy studies; EMA/MHRA guidance on investigational compounds
